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Prognostic Factors in 3315 Completely Resected Cases of
Clinical Stage I Non-small Cell Lung Cancer in Japan
Teruaki Koike, MD,* Ryosuke Tsuchiya, MD,† Tomoyuki Goya, MD,‡ Yasunori Sohara, MD,§
and Etsuo Miyaoka, PhD
Background: The objective of this retrospective study was to
identify prognostic factors in completely resected clinical (c-) stage
I non-small cell lung cancer cases.
Methods: In 2001, the Japanese Joint Committee of Lung Cancer
Registry collected data on the outcome and clinicopathological
profiles of 7408 patients who had undergone resection for primary
lung cancer in 1994. They included 3315 c-stage I patients who
underwent complete resection, and in this study attempted to iden-
tify prognostic factors in the c-stage IA and c-stage IB cases.
Results: The overall 5-year survival rate was 66.5%: 74.7% in the
2085 c-stage IA cases and 52.5% in the 1230 c-stage IB cases. The
survival curve of the c-stage IA cases was higher than that of
the c-stage IB cases. Multivariate analysis of the c-stage IA cases
revealed six factors that predicted a significantly better outcome:
age, gender, pathological (p-) T status, p-N status, nodal dissection,
and tumor diameter (2 cm), and the same analysis of the c-stage IB
cases revealed six factors: age, gender, p-T status, p-N status,
operative procedure, and tumor diameter (5 cm). The c-stage IA
patients whose tumor diameter was 2 cm or less had a higher
survival rate than the patients whose tumor diameter was more than
2 cm, and the c-stage IB patients whose tumor diameter was less
than 5 cm had a higher survival rate than the patients whose tumor
diameter was 5 cm or more.
Conclusion: Tumor size is an independent prognostic factor for
postoperative survival in c-stage I patients.
Key Words: Clinical stage I lung cancer, Survival, Prognostic
factor, Limited pulmonary resection, Maximum tumor diameter.
(J Thorac Oncol. 2007;2: 408–413)
Lung cancer is a major cause of cancer deaths worldwide.Because there is no comprehensive registration system for
resected lung cancer, there have been only a few reports on
the postoperative survival rate in series of 1000 or more
patients.1–6 The Japanese Joint Committee of Lung Cancer
Registry, which was established by the Japan Lung Cancer
Society and Japanese Association for Chest Surgery, con-
ducted a retrospective study of the outcome and clinicopath-
ogical profiles of patients who had undergone resection for
primary lung cancer in 1994. In 2001, the Committee sent out
a questionnaire and obtained 7408 replies from 303 institu-
tions. The data obtained was reported by Goya et al.7 in 2005.
In their report, the registered cases were classified by clinical
stage, and 59% were clinical stage I. Most clinical stage I
patients are treated surgically. Because physicians need prog-
nostic factors to select the most appropriate operative proce-
dure for lung cancer patients, this study attempted to retro-
spectively identify the prognostic factors in patients who had
undergone complete resection.
PATIENTS AND METHODS
Patients
In 2001, the Japanese Joint Committee of Lung Cancer
Registry accumulated data on 7408 primary lung cancer
patients operated on at 303 institutions in 1994. Because a
total of 11,227 patients had been operated on for primary lung
cancer in Japan in 1994, the data accumulated represented
66% of the cases of resection for primary lung cancer that
year.8 The Committee mailed a questionnaire to the institu-
tions and then collected them. The questionnaire contained 29
items, including questions concerning age; gender; clinical
(c-) T, c-N, c-M, c-stage; operative procedure; extent of
lymph node dissection; pathological (p-) T, p-N, p-M, p-
stage; histological type; maximum tumor diameter; curabil-
ity; and survival time. The classification of the lung cancer
patients was according to the Union Internationale Contre
Cancre staging system for lung cancer published in 1997.9 In
1994, the T factor was assessed by plain chest radiography
and computed tomography of the chest. The N factor was
assessed by computed tomography of the chest, and the M
factor was assessed by computed tomography of the chest,
brain, and abdomen and bone scintigraphy. The 3315 subjects
selected met the following criteria (1) clinical stage I, (2)
non-small cell lung cancer, (3) complete resection, (4) no
history of treatment, but cases of a death within 30 days after
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operation were excluded. The age distribution was 13 to 90
years, and the average age was 64.5 years. Sixty-three percent
of the subjects were male, 63% were c-stage IA patients, and
37% were c-stage IB patients. Of the 3315 c-stage I patients,
2483 were p-stage I, accounting for 74.9% of the c-stage I
patients. Of the 2085 c-stage IA patients, 1508 were p-stage
IA (72.4%), and of the 1230 c-stage IB patients, 680 were
p-stage IB (55.4%). Sixty-six percent had adenocarcinoma,
27% had squamous cell carcinoma, and 7% had other types.
In 1994, the standard operative procedure for primary lung
cancer in Japan was lobectomy plus mediastinal lymph node
dissection (ND2); mediastinal lymph node dissection had not
been performed in approximately 18% of cases. The reason
why it has not been performed is unknown.
Statistical Analysis
Survival time was measured from the date of surgery to
the date of the most recent follow-up examination. Survival
was calculated by the Kaplan-Meier method, and differences
in survival were assessed by log-rank analysis. Multivariate
analysis for prognostic factors was performed according to
FIGURE 1. Postoperative survival curve. The survival curve
of the clinical stage IA patients was significantly higher than
that of the clinical stage IB patients (p  0.0001).
TABLE 1. Overall 5-Year Survival Rates of the Clinical Stage I
Patients According to Potential Prognostic Factors (n  3315)
Variable
No. of
Patients
5-yr
Survival, % p
Age
70 yr 2211 71.8 0.001
70 yr 1104 56.0
Gender
Female 1236 73.7 0.001
Male 2079 62.2
Histology
Squamous cell
carcinoma
893 61.9 0.001 (Sq vs. Ad)
Adenocarcinoma 2202 69.0 0.001 (Ad vs. other)
Other 220 60.5 0.704 (Sq vs. other)
Clinical T
cT1 2085 74.7 0.001
cT2 1230 52.5
Pathological T
pT1 1931 77.3 0.001 (pT1 vs. pT2)
pT2 1183 53.0 0.005 (pT2 vs. pT34)
pT3–4 201 42.1 0.001 (pT1 vs. pT34)
Pathological N
pN0 2627 73.9 0.001 (pN0 vs. pN1)
pN1 310 45.1 0.001 (pN1 vs. pN2)
pN2 378 32.8 0.001 (pN0 vs. pN2)
Pathological M
pM0 3284 66.8 0.001
pM1 31 35.5
Operative procedure
Pneumonectomy or
lobectomy
3140 66.7 0.063
Limited resection 175 63.0
Nodal dissection
ND 0–1 590 58.8 0.001
ND 2 2725 68.2
Limited resection, segmentectomy or wedge resection; ND, lymph node dissection;
ND0, without lymph node dissection or lymph node sampling; ND1, intrapulmonary
and hilar lymph node dissection; ND2, ND1 plus mediastinal lymph node dissection.
TABLE 2. Multivariate Analysis of Survival in the Clinical
Stage I Cases: Cox Proportional Hazard Model
Variable HR (95% CI) p
Age
70 yr Reference
70 yr 1.673 (1.491–1.978) 0.001
Gender
Female Reference
Male 1.395 (1.224–1.590) 0.001
Histology
Squamous cell carcinoma Reference
Adenocarcinoma 0.998 (0.872–1.141) 0.972
Other 1.190 (0.949–1.493) 0.132
Clinical T status
cT1 Reference
cT2 1.202 (1.030–1.403) 0.019
Pathological T status
pT1 Reference
pT2 1.805 (1.537–2.121) 0.001
pT3–4 2.307 (1.853–2.871) 0.001
Pathological N status
pN0 Reference
pN1 2.132 (1.806–2.516) 0.001
pN2 3.443 (2.984–3.972) 0.001
Pathological M status
pM0 Reference
pM1 1.591 (1.020–2.483) 0.041
Operative procedure
Pneumonectomy or lobectomy Reference
Limited resection 1.410 (1.094–1.818) 0.008
Nodal dissection
ND 0–1 Reference
ND 2 0.734 (0.634–0.849) 0.001
HR, hazard ratio; CI, confidence interval; Limited resection, segmentectomy or
wedge resection; ND, lymph node dissection.
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the Cox proportional hazard regression model. A p value less
than 0.05 was considered statistically significant.
RESULTS
All deaths were included in the calculations of the
postoperative survival rates. The overall 5-year survival rate
was 66.5% in c-stage I (n  3315), 74.7% in c-stage IA (n 
2085), and 52.5% in c-stage IB (n  1230) (Figure 1). The
survival curve of the c-stage IA patients was significantly
higher than that of the c-stage IB patients (p  0.0001). Nine
factors affected postoperative survival in c-stage I disease:
age, gender, tumor histology, c-T status, p-T status, p-N
status, p-M status, operative procedure, and extent of lymph
node dissection. Univariate analysis of the c-stage I cases
revealed a significantly better outcome when positive for the
following variables: younger than 70 years of age, female,
adenocarcinoma, c-T1, p-T1, p-N0, p-M0, and mediastinal
nodal dissection (Table 1). Multivariate analysis using these
nine prognostic factors demonstrated that age, gender, c-T
status, p-T status, p-N status, p-M status, operative procedure,
and extent of nodal dissection were significant prognostic
factors (Table 2). Next we tested the nine prognostic factors
in relation to the c-IA cases and the c-IB cases. The factor c-T
status was excluded as a prognostic factor from the analysis
of these groups, and maximum tumor size was added. Uni-
variate analysis of the c-IA cases demonstrated the following
factors as predictors of a good outcome: younger than 70
years of age, female, p-T1, p-N0, p-M0, pneumonectomy or
lobectomy, mediastinal nodal dissection, tumor diameter of 2
cm or less in the resected specimen (Table 3). Multivariate
analysis using these nine prognostic factors demonstrated that
age, gender, p-T status, p-N status, extent of nodal dissection,
and maximum tumor diameter were significant prognostic
factors (Table 4). Univariate analysis of the c-IB cases dem-
onstrated the following factors as predictors of a good out-
come: younger 70 years of age, female, p-T1, p-N0, pneu-
monectomy or lobectomy, mediastinal nodal dissection,
tumor diameter less than 5 cm (Table 5). Multivariate anal-
TABLE 3. Overall Survival Rates of the Clinical Stage IA
Patients (n  2085)
Variable
No. of
Patients
5-yr
Survival, % p
Age
70 yr 1459 78.2 0.001
70 yr 626 66.7
Gender
Female 872 80.7 0.001
Male 1213 70.4
Histology
Squamous cell
carcinoma
448 69.1 0.178 (Sq vs. Ad)
Adenocarcinoma 1511 76.8 0.001 (Ad vs. others)
Other 220 60.5 0.360 (Sq vs. others)
Pathological T
pT1 1771 78.5 0.001 (pT1 vs. pT2)
pT2 243 55.0 0.560 (pT2 vs. pT34)
pT3–4 71 48.9 0.001 (pT1 vs. pT34)
Pathological N
pN0 1745 80.1 0.001 (pN0 vs. pN1)
pN1 153 55.4 0.002 (pN1 vs. pN2)
pN2 187 40.3 0.001 (pN0 vs. pN2)
Pathological M
pM0 2072 75.0 0.001
pM1 13 38.5
Operative procedure
Pneumonectomy or
lobectomy
1930 75.2 0.001
Limited resection 155 68.6
Nodal dissection
ND 0–1 394 66.2 0.001
ND 2 1691 76.7
Tumor diameter
2 cm 1068 80.3 0.001
2 cm 1017 68.9
Limited resection, segmentectomy or wedge resection; ND, lymph node dissection.
TABLE 4. Multivariate Analysis of Survival in the Clinical
Stage IA Cases: Cox Proportional Hazard Model
Variable HR (95% CI) p
Age
70 yr Reference
70 yr 1.557 (1.319–1.838) 0.001
Gender
Female Reference
Male 1.479 (1.233–1.774) 0.001
Histology
Squamous cell carcinoma Reference
Adenocarcinoma 0.829 (0.680–1.011) 0.064
Other 0.885 (0.619–1.266) 0.503
Pathological T status
pT1 Reference
pT2 1.850 (1.493–2.292) 0.001
pT3–4 2.281 (1.625–3.202) 0.001
Pathological N status
pN0 Reference
pN1 2.168 (1.686–2.789) 0.001
pN2 3.769 (3.053–4.653) 0.001
Pathological M status
pM0 Reference
pM1 1.543 (0.752–3.166) 0.237
Operative procedure
Pneumonectomy or lobectomy Reference
Limited resection 1.258 (0.938–1.687) 0.125
Nodal dissection
ND 0–1 Reference
ND 2 0.663 (0.542–0.810) 0.001
Tumor diameter
2 cm Reference
2 cm 1.315 (1.108–1.561) 0.020
HR, hazard ratio; CI, confidence interval; Limited resection, segmentectomy or
wedge resection; ND, lymph node dissection.
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ysis using these nine prognostic factors demonstrated that
age, gender, p-T status, p-N status, operative procedure, and
maximum tumor diameter were significant prognostic factors
(Table 6).
DISCUSSION
The mass-screening program for lung cancer in Japan
supported by the national government under the Health and
Medical Service Law for the Aged was started in 1987.10
After nationwide implementation of the program, sometimes
in combination with computed tomography scanning of the
chest, the number of resections for early-stage lung cancer
began to increase.11,12 In 2001, the Japanese Joint Committee
of Lung Cancer Registry investigated the outcome and clin-
icopathological profiles of patients who had undergone resec-
tion for primary lung cancer in 1994.7 The 5-year survival
rate of all 6644 patients with non-small cell lung cancer was
52.6%. The 5-year survival rate was 66.5% for the com-
pletely resected c-stage I cases as a whole, with 74.7% for the
c-stage IA cases and 52.5% for the c-stage IB cases.
There have been several reports on the postoperative
survival of c-stage I cases (Table 7). Mountain1 reported on
the survival rate of patients treated between 1975 and 1988
and stated that the 5-year survival rate was 61% for the
c-stage IA cases and 38% for the c-stage IB cases. These
survival rates were lower, perhaps because the subjects in
their report included patients treated by other modalities and
not just by surgery. Conversely, the survival rates were higher
in surgically resected c-stage I cases. Suzuki et al.13 reported
a 5-year survival rate was 66.5% for 365 c-I3 cases who were
operated on between 1987 and 1994. The lowest 5-year
survival rate for c-stage IA cases was 66.4%, and the highest
was 77.1%, the lowest and highest rates c-stage IB cases were
44.0% and 53.8%, respectively.3,13,14 Suzuki et al.13 investi-
gated the prognostic factors in c-stage I cases and reported
that a multivariate analysis revealed clinical T2 status and
preoperative high serum carcinoembryonic antigen level as
independent predictors of a poor outcome. Multivariate anal-
TABLE 5. Overall Survival Rates of the Clinical Stage IB
Patients (n  1230)
Variable
No. of
Patients
5-yr
Survival, % p
Age
70 yr 752 59.3 0.001
70 yr 478 41.7
Gender
Female 364 56.8 0.006
Male 866 50.7
Histology
Squamous cell
carcinoma
445 54.7 0.461 (Sq vs. Ad)
Adenocarcinoma 691 51.9 0.747 (Ad vs. other)
Other 94 47.3 0.043 (Sq vs. other)
Pathological T
pT1 160 64.3 0.004 (pT1 vs. T2)
pT2 940 52.5 0.001 (pT2 vs. T34)
pT3–4 130 38.4 0.001 (pT1 vs. T34)
Pathological N
pN0 882 61.5 0.001 (pN0 vs. N1)
pN1 157 35.1 0.004 (pN1 vs. N2)
pN2 191 25.4 0.001 (pN0 vs. N2)
Pathological M
pM0 1212 52.8 0.212
pM1 18 33.3
Operative procedure
Pneumonectomy or
lobectomy
1210 53.1 0.0005
Limited resection 20 20.0
Nodal dissection
ND 0–1 196 43.7 0.005
ND 2 1034 54.2
Tumor diameter
5 cm 954 55.8 0.001
5 cm 276 41.1
Limited resection, segmentectomy or wedge resection; ND, lymph node dissection.
TABLE 6. Multivariate Analysis of Survival in the Clinical
Stage IB Cases: Cox Proportional Hazard Model
Variable HR (95% CI) p
Age
70 yr Reference
70 yr 1.698 (1.444–1.997) 0.001
Gender
Female Reference
Male 1.261 (1.043–1.525) 0.016
Histology
Squamous cell carcinoma Reference
Adenocarcinoma 1.153 (0.960–1.383) 0.127
Other 1.428 (1.060–1.266) 0.019
Pathological T status
pT1 Reference
pT2 1.331 (1.018–1.740) 0.037
pT3–4 1.693 (1.204–2.380) 0.002
Pathological N status
pN0 Reference
pN1 2.106 (1.686–2.629) 0.001
pN2 3.087 (2.536–3.758) 0.001
Pathological M status
pM0 Reference
pM1 1.409 (0.791–2.510) 0.245
Operative procedure
Pneumonectomy or lobectomy Reference
Limited resection 2.118 (1.252–3.583) 0.005
Nodal dissection
ND 0–1 Reference
ND 2 0.840 (0.675–1.046) 0.120
Tumor diameter
5 cm Reference
5 cm 1.460 (1.215–1.754) 0.001
HR, hazard ratio; CI, confidence interval; Limited resection, segmentectomy or
wedge resection; ND, lymph node dissection.
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yses of all factors except serum carcinoembryonic antigen
and serum squamous cell carcinoma antigen levels showed
that clinical T2 status and age 70 years or older were signif-
icant prognostic factors for a poor outcome (Table 8). Iizasa
et al.15 reported that age younger than 70 years, female
gender, and p-T1 were significant prognostic factors for a
good outcome based on a multivariate analysis of p-stage I
cases in which a complete resection with lobectomy had been
performed. Takeda et al.16 reported age and tumor size as
significant prognostic factors for non-small cell lung cancer
cases in which complete resection had been performed and
there were no lymph node metastases. Kawai et al.17 reported
finding that age, gender, and performance status were
significant prognostic factors. Based on the above reports,
it can be concluded that age, gender, and tumor size are
significant prognostic factors for completely resected stage
I lung cancer cases.
Recently many surgeons had been debating the opera-
tive procedure for stage I lung cancer. Pneumonectomy was
the standard surgical procedure when the first successful
surgical resection of lung cancer was reported.18,19 However,
in the 1950s, lobectomy was reported to provide postopera-
tive survival comparable with pneumonectomy, and it has
been the standard surgical procedure ever since.20,21 Limited
pulmonary resection has recently been a attracting increasing
attention for the treatment of peripheral-type small-size lung
cancers. Many investigated the correlation between postop-
erative survival and tumor size in surgically treated stage I
lung cancer cases.5,6,22,23 Therefore, tumor size is a major
prognostic factor for stage I cases and is an important factor
for determining whether limited surgery is indicated.
In conclusion, the Japanese Joint Committee of Lung
Cancer Registry collected the data on outcome and the
clinicopathological data of 7408 patients who underwent
resection for primary lung cancer in 1994. There were 3315
patients with c-stage I non-small cell lung cancer, and their
overall 5-year survival rate was 66.5%: 74.7% for the 2085
c-stage IA and 52.5% for 1230 c-stage IB. The survival curve
TABLE 8. Prognostic Factors in Resected Non-small Cell Lung Cancer Cases
Author/Period
Stage/Operative
Procedure
No. of
Patients Significant Factor in Multivariate Analysis
Suzuki et al.13/1987–1994 c-I/lobectomy 365 Clinical T status (c-T1 vs. c-T2), agea (70 yr vs. 70 yr),
serum CEA (5.0 ng/ml vs. 5.0 ng/ml)
Iizasa et al.15/1985–1997 p-I/lobectomy 402 Age (70 yr vs. 70 yr), sex, tumor size (p-T1 vs. p-T2)
Takeda et al.16/1992–1996 p-N0/lobectomy or 603 Age (60 yr vs. 60 yr), tumor size (50 mm vs.
pneumonectomy 50 mm)
Kawai et al.17/1992–1996 p-IA/all procedures 3082 Age (70 yr vs. 70 yr), sex, PS (0 vs. 1)
This study/1994 c-I/all procedures 3315 Age (70 yr vs. 70 yr), sex, c-T status, p-T status, p-N
status, p-M status, operative procedure, nodal dissection
c-IA/all procedures 2085 Age, sex, p-T status, p-N status, modal dissection,
tumor size (2 cm vs. 2 cm)
c-IB/all procedures 1230 Age, sex, p-T status, p-N status, operative procedure, tumor
size (5 cm vs. 5 cm)
a Multivariate analysis using all factors except serum carcinoembryonic antigen (CEA) and serum squamous cell carcinoma antigen
(SCC) levels.
c-I, clinical stage I; p-I, pathological stage I; p-N0, pathologically lymph-node negative; c-T, clinical T status; p-T, pathological T status;
p-N, pathological N status; PS, performance status; p-M, pathological M status.
TABLE 7. Survival Rates of the Clinical Stage I Patients
Author/Period
Clinical
Stage
No. of
Patients Histology
Treatment
Modality
5-yr
Survival, %
Mountain1/1975–1988 c-IA 687 NSCLC Unknown 61
c-IB 1189 NSCLC Unknown 38
Naruke et al.3/1964–1997 c-IA 786 All Surgery 70.8
c-IB 759 All Surgery 44.0
Suzuki et al.13/1987–1994 c-I 365 NSCLC Surgery 66.5
c-IA 198 NSCLC Surgery 77.1
c-IB 167 NSCLC Surgery 53.8
Yoshino et al.14/1979–1999 c-IA 347 NSCLC Surgery 66.4
c-IB 298 NSCLC Surgery 48.3
This study/1994 c-I 3315 NSCLC Surgery 66.5
c-IA 2085 NSCLC Surgery 74.7
c-IB 1230 NSCLC Surgery 52.5
c-I, clinical stage I; c-IA, clinical stage IA; c-IB, clinical stage IB; NSCLC, non-small cell lung cancer.
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of the c-stage IA cases was higher than that of the c-stage
IB cases. Multivariate analysis of the c-stage I cases
revealed eight factors that predicted a significantly better
outcome: age (younger than 70 years old), gender (fe-
male), c-T1, p-T1, p-N0, p-M0, operative procedure (pneu-
monectomy or lobectomy), and nodal dissection (medias-
tinal lymph node dissection).
Multivariate analysis of the clinical stage IA cases re-
vealed six factors that predicted a significantly better out-
come: age, gender, pathological T status, pathological N
status, nodal dissection, and maximum tumor diameter (2
cm), and the same analysis of the clinical stage IB cases
revealed six factors that predicted a significantly better out-
come: age, gender, pathological T status, pathological N
status, operative procedure, and maximum tumor diameter
(5 cm). The factors that predicted a better outcome that
were common to the completely resected clinical stage I, IA,
and IB cases were age, gender, pathological T status, and
pathological N status.
The clinical stage IA patients whose maximum tumor
diameter was 2 cm or less had a higher survival rate than the
patients whose maximum tumor diameter was more than 2
cm, and the clinical stage IB patients whose maximum tumor
diameter was less than 5 cm had a higher survival rate than
the patients whose maximum tumor diameter was 5 cm or
more. Thus, tumor size was the major prognostic factor for
postoperative survival.
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